TrialCell reports. Medicine2024

Preclinical study and phase 2 trial of neoadjuvant pyrotinib combined with chemotherapy in luminal/HER2-low breast cancer: PILHLE-001 study.

Chang Gong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.